Decellularization‐Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202302660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Haocheng Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai,…. Hauptthemen laut MEDLINE: Extracellular Matrix, Inflammation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Talent Development Fund, Shanghai Jiao Tong University Science and Technology Innovation Special Fund.
Abstract (Originalsprache)
Xenografts have emerged as a promising option for severe tendon defects treatment. However, despite undergoing decellularization, concerns still remain regarding the immunogenicity of xenografts. Because certain components within the extracellular matrix also possess immunogenicity. In this study, a novel strategy of post‐decellularization modification aimed at preserving the endogenous capacity of cells on collagen synthesis to mask antigenic epitopes in extracellular matrix is proposed. To implement this strategy, a human‐derived rosiglitazone‐loaded decellularized extracellular matrix (R‐dECM) is developed. R‐dECM can release rosiglitazone for over 7 days in vitro. By suppressing M1 macrophage polarization, R‐dECM protects the migration and collagen synthesis abilities of tendon‐derived stem cells (TDSCs), while also stabilizing the phenotype of M2 macrophages in vitro. RNA sequencing reveals R‐dECM can mitigate the detrimental crosstalk between TDSCs and inflammatory cells. When applied to a rat patellar tendon defect model, R‐dECM effectively inhibits early inflammation, preventing chronic inflammation. Its duration of function far exceeds the release time of rosiglitazone, implying the establishment of immune evasion, confirming the effectiveness of the proposed strategy. And R‐dECM demonstrates superior tendon repair outcomes compared to dECM. Thus, this study provides a novel bioactive scaffold with the potential to enhance the long‐term clinical outcomes of xenogeneic tendon grafts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China.
ORCID-Profile: Jia Jiang
Förderung
- National Natural Science Foundation of China
- Shanghai Talent Development Fund
- Shanghai Jiao Tong University Science and Technology Innovation Special Fund
- Shanghai Science and Technology Committee
- Foundation of National Center for Translational Medicine (Shanghai) SHU Branch
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Jin, H., Kang, Y., Gao, H., Lin, Z., Huang, D., Zheng, Z., Zhao, J., Wang, L., & Jiang, J. (2024). Decellularization‐Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202302660
Vancouver
Jin H, Kang Y, Gao H, Lin Z, Huang D, Zheng Z, et al. Decellularization‐Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202302660
BibTeX
@article{Jin2024,
author = {Jin, Haocheng and Kang, Yuhao and Gao, Haihan and Lin, Zhiqi and Huang, Dongcheng and Zheng, Zhi and Zhao, Jinzhong and Wang, Liren and Jiang, Jia},
title = {Decellularization‐Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202302660}
}
EUVIMED